Teva is reportedly planning to lay-off up to 1,500 staff at Cephalon, less than a month after it acquired the US biopharmaceuticals firm.
After agreeing the $6.8bn deal earlier this year Teva said it would lead to $500m worth of synergies, a substantial part of which would come form the elimination of duplicate activities, but the Israeli pharma company has yet to confirm any details.
via pmlive.com
No comments:
Post a Comment